+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Influenza Medication Market by Route of Administration, Form, Drug Class, Distribution Channel, End User - Global Forecast to 2030- Product Image
Influenza Medication Market by Route of Administration, Form, Drug Class, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Influenza Medication Market by Route of Administration, Form, Drug Class, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 193 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888966
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The influenza medication market is undergoing continual transformation, driven by innovative therapeutics, technology advances, and evolving global healthcare needs. Understanding the current ecosystem and strategic outlook is essential for decision-makers committed to meeting demand, controlling costs, and anticipating regulatory shifts.

Market Snapshot: Influenza Medication Market Growth Trends

The influenza medication market expanded from USD 3.60 billion in 2024 to USD 3.79 billion in 2025, with a forecasted CAGR of 5.04% projected to reach USD 4.84 billion by 2030. This upward trajectory is propelled by advancing antiviral classes, diversified drug delivery modalities, and rising global healthcare expenditures. The sector’s competitive landscape is shaped by robust R&D pipelines, digital health integration, and the adoption of adaptive supply strategies to address both seasonal surges and pandemic risks. Senior leaders need to factor these qualitative drivers into their resource allocation and growth initiatives.

Scope & Segmentation of the Influenza Medication Market

  • Route of Administration: Inhalation, intravenous, and oral (including both suspension and tablet formats)
  • Form: Injection, powder inhaler, suspension, tablet (amantadine, baloxavir marboxil, oseltamivir, rimantadine)
  • Drug Class: Endonuclease inhibitors, M2 ion channel inhibitors (amantadine, rimantadine), neuraminidase inhibitors (oseltamivir, peramivir, zanamivir)
  • Distribution Channel: Hospital pharmacy, online pharmacy, retail pharmacy
  • End User: Home care, hospitals, outpatient clinics
  • Geographic Coverage: Americas (including granular U.S. states and major economies), Europe Middle East & Africa (covering leading Western European and emerging markets), Asia-Pacific (including China, India, Japan, and other significant markets)
  • Key Companies Profiled: Hoffmann-La Roche AG, GlaxoSmithKline plc, CSL Seqirus Pty Ltd, Sanofi Pasteur SA, AstraZeneca plc, Shionogi & Co., Ltd, BioCryst Pharmaceuticals Inc., Cipla Ltd, Teva Pharmaceutical Industries Ltd, Sandoz International GmbH

Key Takeaways for Strategic Decision-Making

  • Novel antiviral mechanisms and endonuclease inhibitors are reshaping therapeutic approaches and accelerating product development pipelines.
  • Growth in digital health tools is improving remote monitoring, supporting adherence, and enhancing enrollment in clinical trials, which streamlines patient management.
  • Regional diversity across policy, market access, and reimbursement calls for localized approaches to distribution and implementation.
  • The rise of generic and biosimilar entrants is intensifying competition, particularly in mature product segments and emerging geographies.
  • Enhanced supply chain resilience through regional production hubs and multi-sourced supply networks is critical to minimizing disruption risks.
  • Stakeholder engagement with regulatory authorities is facilitating faster approvals and broader market access for next-generation therapeutics.

2025 Tariff Impact on Market Dynamics

United States trade policy updates in 2025 are set to increase procurement costs for both active pharmaceutical ingredients and finished influenza medications. Tariff-related headwinds are driving manufacturers to reassess partnerships, invest in domestic and near-shore production, and adopt digital platforms to offset logistical uncertainties. These adjustments are influencing contract structures throughout the value chain, requiring proactive coordination to preserve cost efficiency and market stability. Advanced analytics and continuous manufacturing are becoming important means to counterbalance these emerging cost pressures within the influenza medication market.

Methodology & Data Sources

This analysis is grounded in structured interviews with infectious disease experts, hospital pharmacy directors, and market leaders, complemented by in-depth reviews of regulatory data, industry filings, and peer-reviewed literature. Data integrity is maintained by triangulating quantitative findings with qualitative insights across multiple analyst teams, ensuring a comprehensive and reliable foundation for trend assessment and strategic guidance.

Why This Report Matters

  • Empowers executives to anticipate shifting market dynamics and regulatory challenges with actionable, data-driven insights.
  • Guides portfolio optimization through deeper understanding of regional differences, new therapy options, and route-of-administration trends.
  • Supports risk mitigation by highlighting supply chain vulnerabilities and emerging opportunities in digital healthcare platforms.

Conclusion

The influenza medication market demands agile strategies, data-driven planning, and continual adaptation to emerging science and trade changes. Use this research to inform risk management and growth decisions in a rapidly evolving therapeutic landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Influenza Medication Market, by Route of Administration
8.1. Introduction
8.2. Inhalation
8.3. Intravenous
8.4. Oral
8.4.1. Suspension
8.4.2. Tablet
9. Influenza Medication Market, by Form
9.1. Introduction
9.2. Injection
9.3. Powder Inhaler
9.4. Suspension
9.5. Tablet
9.5.1. Amantadine
9.5.2. Baloxavir Marboxil
9.5.3. Oseltamivir
9.5.4. Rimantadine
10. Influenza Medication Market, by Drug Class
10.1. Introduction
10.2. Endonuclease Inhibitors
10.3. M2 Ion Channel Inhibitors
10.3.1. Amantadine
10.3.2. Rimantadine
10.4. Neuraminidase Inhibitors
10.4.1. Oseltamivir
10.4.2. Peramivir
10.4.3. Zanamivir
11. Influenza Medication Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Influenza Medication Market, by End User
12.1. Introduction
12.2. Home Care
12.3. Hospitals
12.4. Outpatient Clinics
13. Americas Influenza Medication Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Influenza Medication Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Influenza Medication Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Hoffmann-La Roche AG
16.3.2. GlaxoSmithKline plc
16.3.3. CSL Seqirus Pty Ltd
16.3.4. Sanofi Pasteur SA
16.3.5. AstraZeneca plc
16.3.6. Shionogi & Co., Ltd
16.3.7. BioCryst Pharmaceuticals, Inc.
16.3.8. Cipla Ltd
16.3.9. Teva Pharmaceutical Industries Ltd
16.3.10. Sandoz International GmbH
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. INFLUENZA MEDICATION MARKET MULTI-CURRENCY
FIGURE 2. INFLUENZA MEDICATION MARKET MULTI-LANGUAGE
FIGURE 3. INFLUENZA MEDICATION MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. INFLUENZA MEDICATION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. INFLUENZA MEDICATION MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. INFLUENZA MEDICATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY POWDER INHALER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR MARBOXIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ENDONUCLEASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 62. CANADA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. CANADA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 64. CANADA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 65. CANADA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 66. CANADA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. CANADA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 68. CANADA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 69. CANADA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. CANADA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 73. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 74. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 75. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 77. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 78. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 119. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 120. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 121. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 123. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 124. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 128. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 129. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 130. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 131. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 132. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 133. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. ITALY INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. ITALY INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 146. ITALY INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 147. ITALY INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 148. ITALY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. ITALY INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 150. ITALY INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 151. ITALY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. ITALY INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 155. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 156. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 157. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 158. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 159. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 160. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 191. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 192. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 193. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 194. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 195. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 196. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. QATAR INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. QATAR INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 209. QATAR INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 210. QATAR INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 211. QATAR INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 212. QATAR INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 213. QATAR INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 214. QATAR INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. QATAR INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 218. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 219. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 220. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 221. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 222. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 223. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 245. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 246. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 247. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 248. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 249. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 250. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 254. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 255. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 256. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 257. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 258. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 259. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 260. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 272. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 273. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 274. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 275. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 276. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 277. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. POLAND INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 280. POLAND INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 281. POLAND INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 282. POLAND INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 283. POLAND INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 284. POLAND INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 285. POLAND INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 286. POLAND INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. POLAND INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 289. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 296. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 305. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 306. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 307. CHINA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 308. CHINA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 309. CHINA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 310. CHINA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 311. CHINA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 312. CHINA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 313. CHINA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 314. CHINA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 315. CHINA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 316. INDIA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 317. INDIA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 318. INDIA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 319. INDIA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 320. INDIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 321. INDIA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 322. INDIA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 323. INDIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 324. INDIA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 325. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 326. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 327. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 328. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 329. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 330. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2030 (USD MILLION)
TABLE 331. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 332. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 333. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 334. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 335. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 336. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 337. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 338. AUSTRALIA INFLUENZA MEDICATION MAR

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Influenza Medication market report include:
  • Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • CSL Seqirus Pty Ltd
  • Sanofi Pasteur SA
  • AstraZeneca plc
  • Shionogi & Co., Ltd
  • BioCryst Pharmaceuticals, Inc.
  • Cipla Ltd
  • Teva Pharmaceutical Industries Ltd
  • Sandoz International GmbH

Table Information

Report AttributeDetails
No. of Pages193
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.79 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.84 Billion
Compound Annual Growth Rate5.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Seasonal Influenza Epidemiology Forecast 2025-2034 - Product Image

Seasonal Influenza Epidemiology Forecast 2025-2034

  • Report
  • 150 Pages
  • Global
From
Influenza Medication - Global Strategic Business Report - Product Image

Influenza Medication - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Influenza Treatment Market Report 2025 - Product Image

Influenza Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Influenza Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Influenza Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 186 Pages
  • Global
From
Influenza A Virus H5N1 Subtype - Pipeline Insight, 2025 - Product Image

Influenza A Virus H5N1 Subtype - Pipeline Insight, 2025

  • Drug Pipelines
  • 40 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.